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Abstract. 
Trousseau's syndrome is defined as any unexplained thrombotic event that precedes the di-
agnosis of an occult visceral malignancy or appears concomitantly with a tumor. The high inci-
dence of thromboembolic disease in patients with advanced pancreatic carcinoma has been well 
reported. We report a case of Trousseau's syndrome in a 64-year-old man with pancreatic head 
cancer, presenting with acute ischemic stroke one week following pancreaticoduodenectomy. 
The patient was promptly treated with low-molecular-weight heparin without recurrence of 
thromboembolic events during follow-up. 
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INTRODUCTION 
The relationship between venous thromboembolic 
features and malignancy was first described by Ar-
mand Trousseau in 1865 [1]. Two years later, Trous-
seau himself developed this syndrome as a result of 
gastric carcinoma [2]. Cancer has increasingly been 
recognized as a prothrombotic state of the human body. 
Trousseau's syndrome has been applied to various 
clinical conditions, ranging from brain infarction to 
any kind of hypercoagulability associated with any 
malignant disease [1,2]. The clinical manifestations of 
malignancy-related thromboembolism include spon-
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taneously recurrent migratory venous thrombosis, ar-
terial thrombosis, microangiopathy, nonbacterial 
thrombotic endocarditis, or acute or chronic dissemi-
nated intravascular coagulation [3]. New variants of 
Trousseau's syndrome have recently been described, 
including accelerated courses of peripheral vascular 
disease and ischemic heart disease, both of which are 
enhanced by concealed cancer [4,5]. Here we have 
presented an interesting case of Trousseau's syndrome 
associated with pancreatic adenocarcinoma. 
 
CASE REPORT 
A 64-year-old non-smoking male with a history of 
diabetes mellitus and regularly controlled hyperten-
sion presented with anorexia, abdominal pain and 
tea-colored urine. On physical examination, the pa-
tient was apyrexial with jaundice of his skin and sclera, 
and his abdomen was soft and flat without palpable 
mass. Abdominal ultrasound demonstrated a mass in 
the head of the pancreas causing common bile duct 
dilatation. Computerized tomography (CT) showed a 
3.2 cm tumor at the pancreatic head and the uncinate 
process, with distal narrowing and proximal dilation 
up to 1.2 cm of the common bile duct (CBD). The 
tumor was also found to invade the second portion of 
the duodenum and regional lymphadenopathy was 
also noted (Figures 1,2). Endoscopic retrograde chol-
angiopancreatography (ERCP) revealed ulceration in 
the second and third parts of the duodenum, consistent 
with malignant infiltration. A subsequent biopsy of the 
distal CBD wall showed moderate dysplasia. A stent 
was inserted into the common bile duct to decompress 
the biliary tree (Figure 3). Blood test showed a carci-

















Figure 1. Abdominal CT scan showing a tumor of 3.2 
cm in diameter locating at pancreatic head 
and uncinate process, with invasion to the 












































Figure 3. ERCP showing narrowing of distal CBD 

















Figure 4. Brain MRI showing multiple acute infarcts 




(reference range 0-5) and a CA19-9 value of 2001 
U/mL (normal range 0-37). 
Following biliary decompression, the patient un-
derwent pancreaticoduodenectomy uneventfully. Patho-
logical exam confirmed the diagnosis of pancreatic 
ductal adenocarcinoma pT3 N1 M0 stage IIIB, with 
invasion of the duodenal wall, ampulla of Vater and 
peripancreatic soft tissue. Lymphovascular and peri-
neural invasion was also present. The surgical margin 
was negative. Postoperative blood test showed CEA of 
2.3 ng/mL and CA19-9 at 98.3 U/mL. 
One week following pancreaticoduodenectomy, 
the patient presented with sudden onset of left hemi-
plegia. Magnetic resonance imaging (MRI) of the 
brain demonstrated multiple acute infarcts, predomi-
nantly in the right frontal region and left inferior cer-
ebellum (Figures 4,5,6). His platelet count, prothrom-
bin time (PT), activated partial thromboplastin time 
(aPTT), and international normalized ratio (INR) were 
all within normal ranges. The patient’s D-dimer level 
was elevated at 2353.5 ng/mL (reference range 0-500), 
and fibrinogen was mildly elevated at 888 mg/dL 
(reference range 200-500). Repeated cardiac ultra-
sound showed normal valve function and contractility 
without thrombus. The patient did not have atrial fi-
brillation or arrhythmia throughout the course, which 
eliminated the possibility of acute brain infarction of 
cardiac origin. Based upon this accumulated infor-
mation, a diagnosis of Trousseau's syndrome was 
made. Low-molecular-weight heparin (LMWH) was 
promptly administered. The patient did not develop 
any other thromboembolic event thereafter, and he 
was discharged from the hospital two months postop-
eratively. At the time this article was authored, he was 
receiving physical therapy and LMWH treatment in 
combination with chemotherapy. 
 
DISCUSSION 
Pancreatic carcinoma can be lethal. The median 
survival duration is 6-10 months with locally ad-
vanced disease and 3-6 months in patients with me-
tastases. In addition to the poor overall prognosis, the 
course of the disease may be complicated by throm-
boembolic events as illustrated in this case. 


















Figure 5. Brain MRI showing acute infarction in the 

















Figure 6. Brain MRI showing acute infarcts in the left 
inferior cerebellum (arrow) 
 
 
In our patient, acute ischemic stroke was the first 
manifestation of thromboembolism after radical oper-
ation for pancreatic carcinoma. The relationship be-
tween thromboembolic disease and pancreatic carci-
noma was first described by Sproul in 1938 [6], and is 
now well-documented. The incidence of thromboem-
bolic disease in patients with advanced pancreatic car-
cinoma has been estimated as being as high as 57% 
[7]. In an analysis of 66,000 patients with cancer, it 
was observed that those patients with pancreatic car-
cinoma had the highest risk of thromboembolic dis-
ease [8]. This relationship can be explained by the 
generation of an intrinsic hypercoagulable state in 
pancreatic carcinoma, which seems to be related to 
enhanced tumor growth and angiogenesis [9]. There 
are many features in common between the pathogene-
sis of Trousseau's syndrome and factors that appear to 
facilitate tumor metastases, including roles for tissue 
factor, selectins, platelets, endothelium, and fibrin 
[10-12]. Thus, it is likely that the thrombotic processes 
involved in Trousseau's syndrome also facilitate the 
spread of tumors. Together with the fact that advanced 
visceral carcinomas are mostly incurable, this may 
explain the observation that the search for occult ma-
lignancies has not manifested a large impact on the 
final outcome of cancer survival. 
Concerning therapy for Trousseau's syndrome, 
treatment of the cancer itself is the priority. In addition, 
thrombolytic therapy and thromboprophylaxis are 
necessary. Compared with vitamin K antagonist 
(VKA), heparin is reported to provide a statistically 
significant reduction in thromboembolic events [13]. 
This is because heparin has several antithrombotic 
mechanisms that VKA does not, such as inhibition of 
the binding of mucin to selectin and release of tissue 
factor pathway inhibitor from endothelial binding sites 
[2]. We used LMWH in combination with chemo-
therapy for this patient and continued it as long as 
possible, intending the D-dimer and fibrinogen deg-
radation product (FDP) levels to fall adequately within 
the normal range. According to the results of the latest 
investigations, LMWH is a promising treatment for 
patients whose cancer is complicated by thrombosis. It 
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has recently been reported that there is a trend toward 
decreased mortality with LMWH as compared with 
standard heparin. This reduction in mortality appears 
to be independent of the reduction in thromboembo-
lism and bleeding [14]. The smaller size of LMWH 
molecules makes entry into tumor cells easier than for 
standard heparin molecules, and this may be the rea-
son for its benefit. 
In summary, our case underscores the importance 
of early consideration and accurate diagnosis which 
can lead to appropriate treatment in cancer patients 
with Trousseau's syndrome. 
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